Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial (Q80010826)
Jump to navigation
Jump to search
scientific article published on 01 May 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial |
scientific article published on 01 May 2007 |
Statements
Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial (English)
Gerhard Ehninger
Salah-Eddin Al-Batran
Akin Atmaca
Eberhard Schleyer
Claudia Pauligk
Christian Hosius